This year's volatility appears to have grounded a good many of Wall Street's big boys. In fact, companies such as Pfizer (NYSE: PFE), IBM (NYSE: IBM), and Coca-Cola (NYSE: KO) trade at levels well off their respective 52-week highs. PepsiCo (NYSE: PEP) and Hewlett-Packard (NYSE: HPQ) fit that profile, too, as do Oracle (Nasdaq: ORCL) and ConocoPhillips (NYSE: COP).

Appearances can be deceiving
I say "appears to" because there may be plenty of room for all of the above -- and the broader market in general -- to fall further. As anyone who lived through the bursting of the Internet bubble and the "tech wreck" of 2000 can tell you, market trends have a bad habit of persisting well past the point at which valuation reality would seem to provide a safety net. Just ask investors in S&P-tracking stalwart Vanguard 500 Index (VFINX). A loss of 9% in 2000 was followed by a 12% decline in 2001. Then in 2002, the fund shed more than 22% of its value.

So what are the options for investors contemplating the possibility of a market "double" or perhaps even a "triple" dip? Good question. Here are three possibilities.

1. Double down
Investors with a stomach for volatility and a lengthy timeline might consider plowing fresh dollars into their portfolio's brightest prospects. After all, if you've done your homework, Mr. Market's fire sales provide choice opportunities to snap up shares on the cheap, right?

Could be, yes -- but then again, maybe not. Even apparently bulletproof stocks can inflict further damage to a portfolio when the market refuses to behave rationally -- as it's been known to do on occasion. For that reason, doubling down isn't my preferred option during downturns.

2. Head for the hills
Pulling your money out of the market might seem to be the safest tack, but that can be a money-loser, too: Inflation will erode your purchasing power year-in and year-out. And of course, when the market resumes its upward trajectory, you'll miss out on that opportunity.

The bottom line: Playing it "safe" carries risk, too. With that in mind, I think savvy types should carefully consider this third option.

3. Automate your retirement prep
If you have an asset-allocation game plan in place -- a road map to your financial future built around your timeline and tolerance for risk -- downturns provide opportunities to take advantage of dips (and even double dips) through dollar-cost averaging. Doing so can smooth your ride to retirement bliss, but -- and here's the catch -- only if you've done your homework. Unless you've assembled a basket of securities into a carefully calibrated portfolio -- one that suits your risk tolerance and timeline -- you might be throwing good money after bad.

The Foolish final word
Bottom line: Dollar-cost averaging is only as effective as the vehicle you're sending your monthly moola to. And with thousands of funds, stocks, and exchange-traded funds (ETFs) vying for your hard-earned dollars -- and with most of 'em duds -- choosing well can sometimes seem like a needle-in-the-haystack exercise.

Not to worry. We've found the needles for you and threaded them through a service called Ready Made Millionaire. RMM features a compact, real-money portfolio -- the Fool has a million dollars on the line, in fact -- and it's designed for busy folks in search of a set-and-forget lineup they can use to feather their nest egg.

The service will reopen early next year, but to tide folks over until then, we're offering a special free report -- The 11-Minute Millionaire -- that highlights the three things you need to know before investing another dime in this market. Click here to learn more about Ready-Made Millionaire and snag your free copy of our report.

This article was originally published Aug. 14, 2007. It has been updated.

Shannon Zimmerman runs point on the Fool's Ready-Made Millionaire investment service. Pfizer is a Motley Fool Income Investor pick. Pfizer and Coca-Cola are Motley Fool Inside Value selections. The Fool owns shares of Pfizer. You can check out the Fool's strict disclosure policy right here.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.